– USA, CA – Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Dr. Jing Marantz (M.D., Ph.D.) to its Board of Directors.
“We are very pleased to welcome Dr. Jing Marantz, to the Arcturus Board. Jing is an accomplished industry leader and brings deep clinical and scientific expertise, as well as extensive commercial experience from prominent biopharma leadership roles where she contributed to the successful development and commercialization of numerous approved medicines. Jing will be an invaluable addition as Arcturus rapidly advances the development of its novel vaccines and therapeutic candidates,” said CEO, Joseph Payne.
About Dr. Jing Marantz
Dr. Marantz is an experienced biopharmaceutical industry executive who has held multiple senior level positions in development, medical affairs, business development, and commercial strategy in several therapeutic areas and rare diseases. She is currently SVP, Head of Medical Affairs at Acceleron Pharma, a wholly-owned subsidiary of Merck & Co., Inc. Prior to joining Acceleron in 2020, Dr. Marantz was SVP, Head of Medical Affairs at Alnylam Pharmaceuticals where she built the medical affairs organization into a global footprint across 19 countries and led two successful global product launches (ONPATTRO and GIVLAARI). Prior to Alnylam, she served as VP, Global Medical Affairs, Head of U.S. Medical Affairs and interim Head of Latin America Medical Affairs at Alexion Pharmaceuticals where she was responsible for three marketed rare disease products (SOLIRIS, STRENSIQ, and KANUMA). Dr. Marantz previously held leadership positions at Biogen, ARIAD, and Millennium Pharmaceuticals across development, medical affairs, and business development. She currently serves on the Board of Directors for Krystal Biotech, Inc.
“I’m delighted to join the Arcturus board as the Company advances its vaccine programs, including for COVID-19, while continuing to expand a promising set of mRNA-based therapeutic candidates in clinical development,” said Dr. Marantz. “I look forward to working closely with the team and contributing to their efforts to bring important new vaccines and medicines to patients.”
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza, and other programs to potentially treat ornithine transcarbamylase deficiency, and cystic fibrosis along with partnered programs including glycogen storage disease type III (GSD III), hepatitis B virus, and non-alcoholic steatohepatitis. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio. Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Duke-NUS Medical School, and the Cystic Fibrosis Foundation.
For more information : https://arcturusrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
